Back to News

COVID-19 Resources

Read more from IMPAACT Leadership on the ongoing COVID-19 pandemic and see guidance from the CDC, DAIDS, EMA, FDA, WHO, and more.

ShareShare

Since early 2020, the IMPAACT Network has been closely monitoring the ongoing COVID-19 pandemic. The safety and well-being of IMPAACT study participants, community members, clinical research site staff, and laboratory staff are of utmost importance and the highest priority for our Network. We are still continuing to track all updates and heeding recommendations from national and international health organizations, including the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) regarding the disease.

Consistent with guidance from DAIDS, and in consultation with our NIH partners, action steps are as follows (updated 31 March 2021):

  • IMPAACT P1108, IMPAACT P1115, and IMPAACT 2005 were permitted to resume accrual as of 19 July 2020; IMPAACT 2019 was opened to accrual. IMPAACT 2009, IMPAACT 2017, and IMPAACT 2026 were permitted to resume activities to enroll as of 19 November 2020. Sites confirm contingency planning for COVID-19 impacts prior to resuming or initiating enrollment into any of these studies.

  • Accrual remains paused for IMPAACT 2016 and IMPAACT 2021.

  • Follow-up of participants is continuing, and should continue — to the extent possible and in accordance with relevant government and site-specific institutional policies — with emphasis on safety monitoring and ensuring access to prevention and treatment regimens for participants affected by HIV and TB.

We will continue to provide updates as needed via email and our website. Please stay safe and be well.

 

Resources and Guidance

Guidance for Re-Opening

General Guidance

Country-Specific